YSBs Largest Shareholder Extends Share Lock-Up Period Stock Falls 7 percent - Marketscreener.com
| SHPMY Stock | USD 8.29 0.30 3.75% |
Slightly above 55% of Shanghai Pharmaceuticals' investors are presently thinking to get in. The analysis of overall sentiment of trading Shanghai Pharmaceuticals Holding pink sheet suggests that some investors are interested at this time. Shanghai Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Shanghai Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Shanghai |
YSBs Largest Shareholder Extends Share Lock-Up Period Stock Falls 7 Marketscreener.com
Read at news.google.com
 |
Shanghai Pharmaceuticals Fundamental Analysis
We analyze Shanghai Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Shanghai Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Shanghai Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Asset
Current Asset Comparative Analysis
Shanghai Pharmaceuticals is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Shanghai Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Shanghai Pharmaceuticals pink sheet to make a market-neutral strategy. Peer analysis of Shanghai Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Shanghai Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Shanghai Pharmaceuticals Related Equities
| SHWGY | Shandong Weigao | 10.66 | ||||
| SHTDY | SINOPHARM GROUP | 0.24 | ||||
| SHPMF | Shanghai Pharmaceuticals | 0.00 | ||||
| MCK | McKesson | 0.55 | ||||
| HEGIY | Hengan International | 0.70 |
Additional Tools for Shanghai Pink Sheet Analysis
When running Shanghai Pharmaceuticals' price analysis, check to measure Shanghai Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Shanghai Pharmaceuticals is operating at the current time. Most of Shanghai Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Shanghai Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Shanghai Pharmaceuticals' price. Additionally, you may evaluate how the addition of Shanghai Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.